Document:

Document

Exhibit 10.2

CERTAIN INFORMATION IDENTIFIED WITH [****] HAS BEEN EXCLUDED FROM THIS DOCUMENT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Third Amendment to the Comdata Merchant Agreement

This Third Amendment (“Amendment”) is dated April 14, 2022 (“2022 Amendment Date”) and constitutes an amendment to the December 15, 2010 Comdata Merchant Agreement, as modified by (i) the April 21, 2011 letter from Lisa E. Peerman to Mark R. Young, (ii) the Amended and Restated Amendment to Comdata Merchant Agreement, dated December 14, 2011, and (iii) the December 4, 2020 Second Amendment to Comdata Merchant Agreement (collectively, the “Agreement”) by and between TA Operating LLC (“Merchant”) and Comdata, Inc., as successor in interest to Comdata Network, Inc. (“Comdata”). 
Whereas, Merchant and Comdata wish to adjust the transaction fees and settlement rates that apply to card transactions by certain specified customers;
Now, Therefore, in exchange for mutual promises and other consideration, the sufficiency of which is hereby acknowledged, the parties agree to amend the Agreement as follows:
1.The table entitled “Fees for Authorization of Card Transactions” in Schedule A (v.2020) to the Second Amendment to the Comdata Merchant Agreement is amended such that the customers listed in Schedule C (v.2022), attached hereto, are subject to the transaction fee and Cost plus settlement rates that apply to [****].  There is otherwise no change to the definitions of [****] in Schedule A (v.2020).    
ACCEPTED AND AGREED:
						
	TA Operating LLC (“Merchant”)	COMDATA INC. (“Comdata”)
	Signature: __/s/ Lloyd B. Sanford_________
Name:   _Lloyd B. Sanford_______________
Title:    __SVP Sales_________________ 
Date:    __April 22, 2022________________
	Signature: __/s/ Eric Dowdell___________
Name:   ____Eric Dowdell______________
Title:    _____President - NAT___________
Date:    _____April 22, 2022____________Document

Exhibit 10.3

CERTAIN INFORMATION IDENTIFIED WITH [****] HAS BEEN EXCLUDED FROM THIS DOCUMENT BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

Fourth Amendment to the Comdata Merchant Agreement

This Fourth Amendment (“Amendment”) is dated May 20, 2022 and constitutes an amendment to the December 15, 2010 Comdata Merchant Agreement, as modified by (i) the April 21, 2011 letter from Lisa E. Peerman to Mark R. Young, (ii) the Amended and Restated Amendment to Comdata Merchant Agreement, dated December 14, 2011, (iii) the December 4, 2020 Second Amendment to Comdata Merchant Agreement; and (iv) the April 14, 2022 Third Amendment to Comdata Merchant Agreement (collectively, the “Agreement”) by and between TA Operating LLC (“Merchant”) and Comdata, Inc., as successor in interest to Comdata Network, Inc. (“Comdata”). 
Whereas, Merchant and Comdata wish to enable Merchant to accept Comchek Direct payments;
Now, Therefore, in exchange for mutual promises and other consideration, the sufficiency of which is hereby acknowledged, the parties agree to amend the Agreement as follows:
1.Beginning on or before June 1, 2022, and for the duration of the Agreement:
a.Each Merchant site subject to the Agreement shall be enabled to accept payments via Comchek Direct;
b.Merchant shall pay to Comdata a Comchek Direct fee of $[****] per site per month;
c.The Comchek Direct fee shall be deducted from the Merchant’s first settlement of each month.  

ACCEPTED AND AGREED:

									
	TA Operating LLC (“Merchant”)		COMDATA INC. (“Comdata”)

															
	Signature:	   /s/ Lloyd B. Sanford		Signature:	    /s/ Eric Dowdell
					
	Name:	Lloyd B. Sanford		Name:	Eric Dowdell
					
	Title:	SVP Sales		Title:	President - NAT
					
	Date:	June 21, 2022		Date:	June 6, 2022EX-10.1

 Exhibit 10.1 

Exchange Agreement 

July 28, 2022 
 Apellis
Pharmaceuticals, Inc. 
 3.500% Convertible Senior Notes due 2026 

The undersigned investor (the “Investor”), for itself and on behalf of the beneficial owners listed on Exhibit A hereto
(“Accounts”) for whom the Investor holds contractual and investment authority (each, including the Investor if it is a party exchanging Notes (as defined below), an “Exchanging Investor”), hereby agrees to exchange,
with Apellis Pharmaceuticals, Inc., a Delaware corporation (the “Company”), certain 3.500% Convertible Senior Notes due 2026, CUSIP 03753UAB2 (the “Notes”) for shares (“Shares”) of the
Company’s common stock, $0.0001 par value per share (the “Common Stock”), pursuant to this exchange agreement (this “Agreement”). The Investor understands that the exchange (the “Exchange”) is
being made without registration of the offer or sale of the Shares under the Securities Act of 1933, as amended (the “Securities Act”), or any securities laws of any state of the United States or of any other jurisdiction in a
private placement pursuant to the exemption from registration provided by Section 4(a)(2) of the Securities Act and that each Exchanging Investor participating in the Exchange is required to be an institutional “accredited investor”
within the meaning of Rule 501(a)(1), (2), (3) or (7) of Regulation D under the Securities Act that is also a “qualified institutional buyer” within the meaning of Rule 144A under the Securities Act. Capitalized terms used but not
defined in this Agreement have the respective meanings set forth in the indenture, dated as of September 16, 2019, (the “Indenture”) between the Company and U.S. Bank National Association, as trustee (the
“Trustee”). 
 1.    Exchange. On the basis of the representations, warranties and agreements herein contained
and subject to the terms and conditions herein set forth, the Investor hereby agrees to exchange for itself and on behalf of the Exchanging Investors, an aggregate principal amount of the Notes set forth on Exhibit A hereto (the
“Exchanged Notes”) for: 
 (a)    a number of Shares per $1,000 principal amount of such
Exchanged Notes equal to 20.2724; plus 
 (b)    an additional number of Shares per $1,000
principal amount of such Exchanged Notes equal to the quotient of (i) $591.91 divided by (ii) the average of the Daily VWAPs (as defined below) over the Reference Period (as defined below) (the aggregate number of Shares under
clause (a) and (b), the “Exchange Consideration”); 
 in each case, as adjusted in good faith by the Company for any
stock dividend, stock split, stock combination, reclassification or similar transaction occurring on or after the date hereof and prior to the Closing Date; provided that the number of Shares to be exchanged for the Exchanged Notes shall be
rounded down to the nearest whole share for each Exchanging Investor. 
 For the avoidance of doubt, no cash will be paid to any Exchanging
Investor in respect of any accrued and unpaid interest on the Exchanged Notes. 
 Notwithstanding the foregoing, in no event shall the number
of shares of Common Stock issuable under this Agreement and in exchange for other Notes pursuant to any other exchange agreement entered into on or about the date of this Agreement (the “Other Exchange Agreements”) between the
Company and holders of such other Notes with respect to the exchange of Notes for Common Stock exceed 19.9% of the Company’s issued and outstanding Common Stock on the 

  
 1 

 
date hereof (the “Threshold”). If such aggregate amount of shares of Common Stock were to exceed the Threshold, (i) the aggregate number of such shares of Common Stock
to be issued under this Agreement and the Other Exchange Agreements shall be allocated among the Exchanging Investors and the “Exchanging Investors” under the Other Exchange Agreements on a pro rata basis based on the principal amount of
Notes intended to be exchanged by each such Exchanging Investor under this Agreement and the Other Exchange Agreements and (ii) the percentage reduction in the number of shares of Common Stock to be issued under this Agreement pursuant to
clause (i) shall be multiplied by the face amount of the Exchanged Notes and such amount of Exchanged Notes shall not be considered Exchanged Notes, shall not be exchanged hereunder and shall be returned to the Investor. 

“Business Day” means any day other than a Saturday, a Sunday or a day on which the Federal Reserve Bank of New
York is authorized or required by law or executive order to close or be closed. 
 “Daily VWAP” means, for
each Trading Day (as defined below) in the Reference Period (as defined below), the per share volume-weighted average price of the Common Stock as displayed under the heading “Bloomberg VWAP” on Bloomberg page “APLS <equity>
AQR” (or its equivalent successor if such page is not available) in respect of the period from the scheduled open of trading until the scheduled close of trading of the primary trading session on such Trading Day (or if such volume-weighted
average price is unavailable, the Last Reported Sale Price on such day). The “Daily VWAP” shall be determined without regard to after-hours trading or any other trading outside of the regular trading session trading hours. 

“Last Reported Sale Price” of the Common Stock on any date means the closing sale price per share (or if no
closing sale price is reported, the average of the bid and ask prices or, if more than one in either case, the average of the average bid and the average ask prices) on that date as reported in composite transactions for the principal U.S. national
or regional securities exchange on which the Common Stock is traded. 
 “Market Disruption Event” means
(a) a failure by the primary U.S. national or regional securities exchange or market on which the Common Stock is listed or admitted for trading to open for trading during its regular trading session or (b) the occurrence or existence
prior to 1:00 p.m., New York City time, on any Scheduled Trading Day (as defined in the Indenture) for the Common Stock for more than one half-hour period in the aggregate during regular trading hours of any suspension or limitation imposed on
trading (by reason of movements in price exceeding limits permitted by the relevant stock exchange or otherwise) in the Common Stock or in any options contracts or futures contracts relating to the Common Stock. 

“Reference Period” means the period of three (3) consecutive Trading Days commencing on the first Trading
Day following the date hereof. 
 “Trading Day” means a day on which (a) there is no Market Disruption
Event and (b) trading in the Common Stock generally occurs on The Nasdaq Global Select Market or, if the Common Stock is not then listed on The Nasdaq Global Select Market, on the principal other U.S. national or regional securities exchange on
which the Common Stock is then listed or, if the Common Stock is not then listed on a U.S. national or regional securities exchange, on the principal other market on which the Common Stock is then listed or admitted for trading, except that if the
Common Stock is not so listed or admitted for trading, “Trading Day” means a Business Day. 

  
 2 

 The Investor agrees that it and any Exchanging Investor shall not deliver a Notice of Conversion with
respect to any Exchanged Notes and the Investor and each Exchanging Investor shall hold the Exchanged Notes until the Closing (as defined below). In consideration for the performance of their obligations hereunder (including as described in the
immediately preceding sentence), the Company agrees to deliver the Exchange Consideration on the Closing Date (as defined below) to each Exchanging Investor in exchange for its Exchanged Notes. 

The Exchange shall occur in accordance with the procedures set forth in Exhibit B.2 hereto (the “Exchange Procedures”);
provided that each of the Company and the Investor acknowledges that the delivery of the Shares to any Exchanging Investor may be delayed due to procedures and mechanics within the system of American Stock Transfer & Trust Company,
LLC, The Depositary Trust Company (“DTC”) or The Nasdaq Global Select Market (“Nasdaq”) (including the procedures and mechanics regarding the listing of the Shares on Nasdaq) or other events beyond the
Company’s control and that such a delay will not be a default under this Agreement so long as (i) the Company is using its reasonable best efforts to effect such delivery, or (ii) such delay arises due to a failure by Investor to
deliver settlement instructions in accordance with Section 3(s); provided, further, that no delivery of Shares will be made until the Exchanged Notes have been properly submitted for exchange in accordance with the Exchange
Procedures and no accrued interest will be payable by reason of any delay in making such delivery. 
 The closing of the Exchange (the
“Closing”) shall take place remotely via the exchange of documents and signatures at 10:00 a.m., New York City time, on August 4, 2022 (the “Closing Date”), or at such other time and place as the Company and
the Investor may mutually agree. On the Closing Date, subject to satisfaction of the conditions precedent specified herein and the prior receipt by the Company from the Investor of the Exchanged Notes, the Company shall deliver the Shares to the DTC
account specified by the Investor for each relevant Exchanging Investor in Exhibit B.1. All questions as to the form of all documents and the validity and acceptance of the Exchanged Notes and the Exchange Consideration will be determined by
the Company, in its sole discretion, which determination shall be final and binding. Subject to the terms and conditions of this Agreement, the Investor hereby, for itself and on behalf of its Accounts, (a) waives any and all other rights with
respect to such Exchanged Notes and (b) releases and discharges the Company from any and all claims the undersigned and its Accounts may now have, or may have in the future, arising out of, or related to, such Exchanged Notes. 

2.    Representations and Warranties and Covenants of the Company. As of the date hereof and the Closing Date, the Company
represents and warrants to, and covenants with, the Exchanging Investors that: 
 (a)    The Company and
each of its subsidiaries are entities duly organized, validly existing and in good standing under the laws of the jurisdiction in which each is formed, and have the requisite power and authority to own their properties and to carry on their business
as now being conducted, except in the case of the Company’s subsidiaries as would not reasonably be expected to have a material adverse effect on the business, properties, assets, liabilities, operations (including results thereof), or
financial condition of the Company or its subsidiaries, taken as a whole. The Company and each of its subsidiaries is duly qualified as a foreign entity to do business (where such concept exists) and is in good standing in every jurisdiction (where
such concept exists) in which its ownership of property or the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to be so qualified or be in good standing would not reasonably be
expected to have a material adverse effect on the business, properties, assets, liabilities, operations (including results thereof), or condition (financial or otherwise) of the Company or its subsidiaries, taken as a whole. The Company has the
power, authority and capacity to execute and deliver this Agreement, to perform its obligations hereunder, 

  
 3 

 
and to consummate the Exchange contemplated hereby. No consent, approval, order or authorization of, or registration, declaration or filing with any governmental entity is required on the part of
the Company or any of its subsidiaries in connection with the execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the Exchange, except as may be required under any state or federal securities
laws or that may be made or obtained after the Closing without penalty. 
 (b)    This Agreement has been
duly authorized, executed and delivered by the Company and constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except that such enforcement may be subject to
(a) bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or other similar laws affecting or relating to enforcement of creditors’ rights generally and (b) general principles of equity, whether such enforceability is
considered in a proceeding at law or in equity. 
 (c)    This Agreement and consummation of the Exchange
will not violate, conflict with or result in a breach of or default under (i) the charter or bylaws of the Company, (ii) any agreement or instrument to which the Company is a party or by which the Company or any of its assets or
subsidiaries are bound, or (iii) assuming the truth and accuracy of the representations and warranties and compliance with the covenants of the Investor and each Exchanging Investor herein, any laws, regulations or governmental or judicial
decrees, injunctions or orders applicable to the Company and its subsidiaries, except in the case of clauses (ii) or (iii), where such violations, conflicts, breaches or defaults as would not, individually or in the aggregate, materially impair
the ability of the Company to consummate the transactions contemplated by this Agreement. 
 (d)    When
issued, delivered and paid for in the manner set forth in this Agreement, the Shares will (i) be validly issued, fully paid and non-assessable, (ii) be free and clear of any Liens (as defined in
Section 3(c) below), option, equity or other adverse claim thereto, including claims or rights under any voting trust agreements, shareholder agreements or other agreements to which the Company is a party, and (iii) will not be subject to
any preemptive, participation, rights of first refusal or other similar rights under the General Corporation Law of the State of Delaware or any to which the Company is a party (other than any such rights that will be waived prior to the Closing).
Assuming the accuracy of the Investor’s and each Exchanging Investor’s representations and warranties hereunder, the Shares (a) will be issued in the Exchange in reliance on the exemption from the registration requirements of the
Securities Act pursuant to 4(a)(2) of the Securities Act and (b) when issued will be free of any restrictive legend and any restrictions on transfer under Rule 144 promulgated under the Securities Act. 

(e)    The execution of this Agreement by the Company and the consummation by the Company of the
transactions contemplated hereby does not require the consent, approval, authorization, order, registration or qualification of, or filing with, any governmental authority, non-governmental regulatory
authorities (including Nasdaq, other than the filing with Nasdaq of a Listing of Additional Shares notification which the Company will so file prior to the issuance of Shares on the Closing Date), except as may be required under any state or federal
securities laws or that may be made or obtained after the Closing without penalty. 
 (f)    From
January 1, 2022 to the date of this Agreement, the Company has timely filed all reports, schedules, forms, proxy statements, statements and other documents required to be filed by it with the Securities and Exchange Commission (the
“SEC”) pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or timely filed notifications of late filings for any of the foregoing (all of the foregoing
filed prior to the date 

  
 4 

 
hereof and all exhibits and appendices included therein and financial statements, notes and schedules thereto and documents incorporated by reference therein being hereinafter referred to as the
“SEC Documents”). As of their respective dates, the SEC Documents complied in all material respects with the requirements of the Exchange Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC
Documents. 
 (g)    Without the prior written consent of the Investor, the Company shall not disclose
the name of the Investor or any Exchanging Investor in any filing or announcement, unless such disclosure is required by applicable law, rule, regulation or legal process based on advice of counsel. 

(h)    There is no action, lawsuit, arbitration, claim or proceeding pending or, to the knowledge of the
Company, threatened, against the Company that would reasonably be expected to impede the consummation of the Exchange. 

(i)    The Company agrees that it shall, upon request, execute and deliver any additional documents deemed
by the Trustee or transfer agent to be reasonably necessary to complete the Exchange. 
 3.    Representations and Warranties and
Covenants of the Investor. As of the date hereof and as of the Closing Date (except as otherwise set forth below), the Investor hereby, for itself and on behalf of the Exchanging Investors, represents and warrants to, and covenants with, the
Company that: 
 (a)    The Investor and each Exchanging Investor is a corporation, limited partnership,
limited liability company or other entity, as the case may be, duly formed, validly existing and in good standing under the laws of the jurisdiction of its formation. 

(b)    The Investor has all requisite corporate (or other applicable entity) power and authority to execute
and deliver this Agreement for itself and on behalf of the Exchanging Investors and to carry out and perform its obligations under the terms hereof and the transactions contemplated hereby. This Agreement has been duly authorized, executed and
delivered by the Investor and constitutes the legal, valid and binding obligation of the Investor and each Exchanging Investor, enforceable in accordance with its terms, except that such enforcement may be subject to (a) bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium or other similar laws affecting or relating to enforcement of creditors’ rights generally and (b) general principles of equity, whether such enforceability is considered in a proceeding at
law or in equity. If the Investor is executing this Agreement on behalf of an Account, (i) the Investor has all requisite discretionary and contractual authority to enter into this Agreement on behalf of, and, bind, each Account, and
(ii) Exhibit A attached to this Agreement contains a true, correct and complete list of (A) the name of each Account and (B) the principal amount of each Account’s Exchanged Notes, as applicable. 

(c)    As of the date hereof and as of the Closing, each of the Exchanging Investors is the current sole
legal and beneficial owner of the Exchanged Notes set forth on Exhibit A attached to this Agreement. When the Exchanged Notes are exchanged, the Company will acquire good, marketable and unencumbered title thereto, free and clear of all
liens, mortgages, pledges, security interests, restrictions, charges, encumbrances or adverse claims, rights or proxies of any kind (“Liens”). None of the Exchanging Investors has, nor prior to the Closing, will have, in whole or in
part, other than pledges or security interests that an Exchanging Investor may have created in favor of a prime broker under and in accordance with its prime brokerage agreement with such broker, (x) assigned, transferred, hypothecated,
pledged, exchanged, submitted for conversion pursuant to the Indenture or otherwise disposed of any of its Exchanged Notes (other than to the Company pursuant hereto), or (y) given any person or entity any transfer order, power of attorney or
other authority of any nature whatsoever with respect to its Exchanged Notes. 

  
 5 

 (d)    The execution, delivery and performance of this
Agreement by the Investor and compliance by the Investor and each Exchanging Investor with all provisions hereof and the consummation of the transactions contemplated hereby, including the Exchange, will not (i) require any consent, approval,
authorization or other order of, or qualification with, any court or governmental body or agency (except as may be required under the securities or Blue Sky laws of the various states), (ii) constitute a breach or violation of any of the terms or
provisions of, or result in a default under, (x) the organizational documents of any of the Investor or any Exchanging Investor or (y) any material indenture, loan agreement, mortgage, lease or other agreement or instrument to which the
Investor or any of the Exchanging Investors is a party or by which such Investor or Exchanging Investor is bound, or (iii) violate or conflict with any applicable law or any rule, regulation, judgment, decision, order or decree of any court or
any governmental body or agency having jurisdiction over the Investor or any of the Exchanging Investors. 

(e)    The Investor and each Exchanging Investor will comply with all applicable laws and regulations in
effect necessary for each Exchanging Investor to consummate the transactions contemplated hereby and obtain any consent, approval or permission required for the transactions contemplated hereby and the laws and regulations of any jurisdiction to
which the Investor and each such Exchanging Investor is subject, and the Company shall have no responsibility therefor. 

(f)    The Investor and each Exchanging Investor acknowledges that no person has been authorized to give
any information or to make any representation or warranty concerning the Company or the Exchange other than the information set forth herein in connection with the Investor’s and each Exchanging Investor’s examination of the Company and
the terms of the Exchange and the Shares, and the Company does not take, and J. Wood Capital Advisors LLC (the “Placement Agent”) does not take any responsibility for, and neither the Company nor the Placement Agent can provide any
assurance as to the reliability of, any other information that others may provide to the Investor or any Exchanging Investor. 

(g)    The Investor and each Exchanging Investor has such knowledge, skill and experience in business,
financial and investment matters so that it is capable of evaluating the merits and risks with respect to the Exchange and an investment in the Shares. With the assistance of the Investor’s and each Exchanging Investor’s own professional
advisors, to the extent that the Investor and any Exchanging Investor has deemed appropriate, such Exchanging Investor has made its own legal, tax, accounting and financial evaluation of the merits and risks of an investment in the Shares and the
consequences of the Exchange and this Agreement and the Investor and any Exchanging Investor has made its own independent decision that the investment in the Shares is suitable and appropriate for the Investor and any Exchanging Investor. The
Investor and each Exchanging Investor has considered the suitability of the Shares as an investment in light of the Investor and such Exchanging Investor’s circumstances and financial condition and is able to bear the risks associated with an
investment in the Shares. 
 (h)    The Investor confirms that it and each Exchanging Investor is not
relying on any communication (written or oral) of the Company, the Placement Agent or any of their respective affiliates or representatives as investment advice or as a recommendation to acquire the Shares in the Exchange. It is understood that
information provided by the Company, the Placement Agent or any of their respective affiliates and representatives shall not be considered investment advice or a recommendation to participate in the Exchange, and that none of the Company, the
Placement Agent or any of their respective affiliates or representatives is acting or has acted as an advisor to the Investor or any Exchanging Investor in deciding to participate in the Exchange. 

  
 6 

 (i)    The Investor confirms that the Company has not
(i) given the Investor or any Exchanging Investor any guarantee, representation or warranty as to the potential success, return, effect or benefit (either legal, regulatory, tax, financial, accounting or otherwise) of an investment in the
Shares or (ii) made any representation or warranty to the Investor or any Exchanging Investor regarding the legality of an investment in the Shares under applicable legal investment or similar laws or regulations. The Investor confirms that it
and each Exchanging Investor is not relying and has not relied, upon any statement, advice (whether accounting, tax, financial legal or other), representation or warranty by the Company or any of its affiliates or representatives, including, without
limitation, the Placement Agent, except for the representations and warranties made by the Company in this Agreement, and that the Investor has made its own independent decision that the investment in the Shares is suitable and appropriate for the
Investor and the Exchanging Investors. 
 (j)    The Investor and each Exchanging Investor is familiar
with the business and financial condition and operations of the Company and the Investor and each Exchanging Investor has had the opportunity to conduct its own investigation of the Company and the Shares. The Investor and each Exchanging Investor
has had access to the SEC filings of the Company and such other information concerning the Company and the Shares as it deems necessary to enable it to make an informed investment decision concerning the Exchange. The Investor and each Exchanging
Investor has been offered the opportunity to ask such questions of the Company and its representatives and received answers thereto, as it deems necessary to enable it to make an informed investment decision concerning the Exchange. 

(k)    Each Exchanging Investor is an institutional “accredited investor” as defined in Rule
501(a)(1), (2), (3) or (7) under the Securities Act and a “qualified institutional buyer” as defined in Rule 144A under the Securities Act. The Investor agrees to furnish any additional information regarding the Investor or any
Exchanging Investor reasonably requested by the Company or any of its affiliates to assure compliance with applicable U.S. federal and state securities laws in connection with the Exchange. 

(l)    The Investor and each Exchanging Investor is not, and has not been during the consecutive three
month period preceding the date hereof and as of the Closing, will not be, a director, officer or “affiliate” within the meaning of Rule 144 promulgated under the Securities Act (an “Affiliate”) of the Company. To the
Investor’s knowledge, no Exchanging Investor acquired any of the Notes, directly or indirectly, from an Affiliate of the Company. 

(m)    Neither the Investor nor any Exchanging Investor is directly, or indirectly through one or more
intermediaries, controlling or controlled by, or under direct or indirect common control with, the Company. 

(n)    Each Exchanging Investor is acquiring the Shares solely for its own beneficial account, for
investment purposes, and not with a view to, or for resale in connection with, any distribution of the Shares. The Investor and each Exchanging Investor understands that the offer and sale of the Shares have not been registered under the Securities
Act or any state securities laws and are being issued without registration under the Securities Act pursuant to Section 4(a)(2) of the Securities Act, which exemption depends in part upon the investment intent of the Exchanging Investors and
the accuracy of the other representations and warranties made by the Investor or 

  
 7 

 
behalf of the Exchanging Investors in this Agreement. The Investor and the Exchanging Investors understand that the Company is relying upon the representations, warranties and agreements
contained in this Agreement (and any supplemental information provided to the Company by the Investor or any of the Exchanging Investors) for the purpose of determining whether this transaction meets the requirements for such exemption(s) and to
issue the Shares without legends as set forth herein. 
 (o)    The Investor acknowledges that the terms
of the Exchange have been mutually negotiated between the Investor and the Company. The Investor was given a meaningful opportunity to negotiate the terms of the Exchange. 

(p)    The Investor acknowledges that it and each Exchanging Investor had a sufficient amount of time to
consider whether to participate in the Exchange and that neither the Company nor the Placement Agent has placed any pressure on the Investor or any Exchanging Investor to respond to the opportunity to participate in the Exchange. The Investor
acknowledges that neither it nor any Exchanging Investor become aware of the Exchange through any form of general solicitation or advertising within the meaning of Rule 502 under the Securities Act. 

(q)    The Investor acknowledges it and each Exchanging Investor understands that the Company intends to
pay the Placement Agent a fee in respect of the Exchange. 
 (r)    The Investor will, upon request,
execute and deliver, for itself and on behalf of any Exchanging Investor, any additional documents deemed by the Company and the Trustee or the transfer agent to be reasonably necessary to complete the transactions contemplated by this Agreement.

 (s)    No later than one (1) Business Day after the date hereof, the Investor agrees to deliver
to the Company settlement instructions substantially in the form of Exhibit B.1 attached to this Agreement for each of the Exchanging Investors. 

(t)    The Investor and each Exchanging Investor understands that the Company, the Placement Agent and
others will rely upon the truth and accuracy of the foregoing representations, warranties and covenants and agrees that if any of the representations and warranties deemed to have been made by it or any of the Exchanging Investors are no longer
accurate, the Investor shall promptly notify the Company and the Placement Agent prior to the Closing. The Investor understands that, unless the Investor notifies the Company in writing to the contrary before the Closing, each of the Investor’s
and Exchanging Investors’ representations and warranties contained in this Agreement will be deemed to have been reaffirmed and confirmed as of the Closing. If the Investor is exchanging any Exchanged Notes and acquiring the Shares as a
fiduciary or agent for one or more accounts (including for purposes of this Section 3(t), the Accounts which are Exchanging Investors), it represents that (i) it has sole investment discretion with respect to each such account,
(ii) it has full power to make the foregoing representations, warranties and covenants on behalf of such account and (iii) it has contractual authority with respect to each such account. 

(u)    The Investor and each Exchanging Investor acknowledges and the Investor agrees that the Placement
Agent has not acted as a financial advisor or fiduciary to the Investor or any Exchanging Investor and that the Placement Agent and its directors, officers, employees, representatives and controlling persons have no responsibility for making, and
have not made, any independent investigation of the information contained herein or in the Company’s SEC filings and make no representation or warranty to the Investor or any Exchanging Investor, express or

  
 8 

 
implied, with respect to the Company, the Exchanged Notes or the Shares or the accuracy, completeness or adequacy of the information provided to the Investor or any Exchanging Investor or any
other publicly available information, nor shall any of the foregoing persons be liable for any loss or damages of any kind resulting from the use of the information contained therein or otherwise supplied to the Investor or any Exchanging Investor.

 (v)    The Investor and each Exchanging Investor acknowledges and understands that as of the date of
this Agreement and at the time of the Closing, the Company may be in possession of material non-public information not known to the Investor or any Exchanging Investor that may impact the value of the Notes,
including the Exchanged Notes, and the Shares (“Information”) that the Company has not disclosed to the Investor or any Exchanging Investor. The Investor and each Exchanging Investor acknowledges that they have not relied upon the non-disclosure of any such Information for purposes of making their decision to participate in the Exchange. The Investor and each Exchanging Investor understands, based on its experience, the disadvantage to which
the Investor and each Exchanging Investor is subject due to the disparity of information between the Company, on the one hand, and the Investor and each Exchanging Investor, on the other hand. Notwithstanding this, the Investor and each
Exchanging Investor has deemed it appropriate to participate in the Exchange. The Investor agrees that the Company and its directors, officers, employees, agents, stockholders and affiliates shall have no liability to the Investor or any Exchanging
Investor or their respective beneficiaries whatsoever due to or in connection with the Company’s use or non-disclosure of the Information or otherwise as a result of the Exchange, and the Investor hereby
irrevocably waives any claim that it or any Exchanging Investor might have based on the failure of the Company to disclose the Information. 

(w)    The Investor and each Exchanging Investor understands that no federal, state, local or foreign
agency has passed upon the merits or risks of an investment in the Shares or made any finding or determination concerning the fairness or advisability of this investment. 

(x)    The operations of the Investor and each Exchanging Investor have been conducted in material
compliance with the applicable rules and regulations administered or conducted by the U.S. Department of Treasury Office of Foreign Assets Control (“OFAC”), the applicable rules and regulations of the Foreign Corrupt Practices Act
(“FCPA”) and the applicable Anti-Money Laundering (“AML”) rules in the Bank Secrecy Act. The Investor has performed due diligence necessary to reasonably determine that the Exchanging Investors are not named on the
lists of denied parties or blocked persons administered by OFAC, resident in or organized under the laws of a country that is the subject of comprehensive economic sanctions and embargoes administered or conducted by OFAC
(“Sanctions”), are not otherwise the subject of Sanctions and have not been found to be in violation or under suspicion of violating OFAC, FCPA or AML rules and regulations. 

(y)    The Investor and each Exchanging Investor is a resident of the jurisdiction set forth on Exhibit
B.1 attached to this Agreement. 
 4.    Conditions to Obligations of the Investor and the Company. The obligations of the
Investor and the Exchanging Investors and of the Company under this Agreement are subject to the satisfaction at or prior to the Closing of the following conditions precedent: (a) the representations and warranties of the Company contained in
Section 2 hereof (with respect to the Investor and Exchanging Investors) and of the Investor contained in Section 3 hereof (with respect to the Company) shall be true and correct as of the Closing in all respects with the same effect as
though such representations and warranties had been made as of the Closing and (b) no provision of any applicable law or any judgment, ruling, order, writ, injunction, award or decree of any governmental authority shall be in effect prohibiting
or making illegal the consummation of the transactions contemplated by this Agreement. 

  
 9 

 5.    Waiver, Amendment. Neither this Agreement nor any provisions hereof or
thereof shall be modified, changed or discharged, except by an instrument in writing, signed by the Company and the Investor. 

6.    Assignability. Neither this Agreement nor any right, remedy, obligation or liability arising hereunder or by reason hereof
shall be assignable by either the Company or the Investor without the prior written consent of the other. 
 7.    Waiver of Jury
Trial. EACH OF THE COMPANY AND THE INVESTOR HEREBY IRREVOCABLY WAIVES ANY AND ALL RIGHT TO TRIAL BY JURY WITH RESPECT TO ANY LEGAL PROCEEDING ARISING OUT OF THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT. 

8.    Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York,
without giving effect to such state’s rules concerning conflicts of laws that might provide for any other choice of law. 

9.    Submission to Jurisdiction. Each of the Company and the Investor: (a) agrees that any legal suit, action or proceeding
arising out of or relating to this Agreement or the transactions contemplated hereby shall be instituted exclusively in the courts of the State of New York located in the City and County of New York or in the United States District Court for the
Southern District of New York; (b) waives any objection that it may now or hereafter have to the venue of any such suit, action or proceeding; and (c) irrevocably consents to the jurisdiction of the aforesaid courts in any such suit,
action or proceeding. Each of the Company and the Investor agrees that a final judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law.

 10.    Venue. Each of the Company and the Investor irrevocably and unconditionally waives, to the fullest extent it may
legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement in any court referred to in Section 9. Each of the Company and
the Investor irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. 

11.    Service of Process. Each of the Company and the Investor irrevocably consents to service of process in the manner provided
for notices in Section 12. Nothing in this Agreement will affect the right of the Company or the Investor to serve process in any other manner permitted by law. 

12.    Notices. All notices and other communications to the Company provided for herein shall be in writing and shall be deemed to
have been duly given if delivered personally, sent by prepaid overnight courier (providing written proof of delivery) or sent by confirmed facsimile transmission or electronic mail and will be deemed given on the date so delivered (or, if such
day is not a Business Day, on the first subsequent Business Day) to the following addresses, or in the case of the Investor, the address provided on Exhibit B.1 attached to this Agreement (or such other address as the Company or the Investor
shall have specified by notice in writing to the other): 

  
 10 

			
	If to the Company:	  	 Apellis Pharmaceuticals, Inc.
 100 5th
Avenue
 Waltham, MA 02451
 Attention: General
Counsel

		
	with a copy to (which shall not constitute notice):	  	 WilmerHale
 60 State Street

Boston, MA 02109
 Attention: Stuart Falber

 13.    Binding Effect. The provisions of this Agreement shall be binding upon and accrue to the
benefit of the Company, the Investor and the Exchanging Investors and their respective heirs, legal representatives, successors and assigns. This Agreement constitutes the entire agreement between the Company and the Investor with respect to the
subject matters hereof. This Agreement may be executed by one or more of the parties hereto in any number of separate counterparts (including by facsimile or other electronic means, including telecopy, email or otherwise), and all of said
counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed signature page of this Agreement by facsimile or other transmission (e.g., “pdf” or “tif” format) shall be
effective as delivery of a manually executed counterpart hereof. 
 14.    Notification of Changes. After the date of this
Agreement, each of the Company and the Investor hereby covenants and agrees to notify the other upon the occurrence of any event prior to the Closing of the Exchange pursuant to this Agreement that would cause any representation, warranty or
covenant of the Company or the Investor, as the case may be, contained in this Agreement to be false or incorrect. 
 15.    Reliance
by the Placement Agent. The Placement Agent may rely on each representation and warranty of the Company and the Investor made herein or pursuant to the terms hereof with the same force and effect as if such representation or warranty were made
directly to the Placement Agent. The Placement Agent shall be a third-party beneficiary of this Agreement to the extent provided in this Section 15. 

16.    Severability. If any term or provision of this Agreement (in whole or in part) is invalid, illegal or unenforceable in any
jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction. 

17.    Survival. The representations and warranties of the Company and the Investor contained in this Agreement or made by or on
behalf of the Exchanging Investors pursuant to this Agreement shall survive the consummation of the transactions contemplated hereby. 

18.    Termination. This Agreement may be terminated and the transactions contemplated hereby abandoned (a) by mutual
agreement of the Company and the Investor in writing or (b) by either the Company or the Investor if the conditions to such party’s obligations set forth herein have not been satisfied (unless waived by the party entitled to the benefit
thereof), and the Closing has not occurred on or before August 9, 2022 without liability of either the Company or the Investor or the Exchanging Investors, as the case may be; provided that neither the Company nor the Investor shall be released
from liability hereunder if this Agreement is terminated and the transactions abandoned by reason of the failure of the Company or the Investor or any of the Exchanging Investors, as the case may be to have performed its obligations hereunder.
Except as provided above, if this Agreement is terminated and the transactions contemplated hereby are not concluded as described above, this Agreement will become void and of no further force and effect. 

  
 11 

 19.    Taxation. The Investor acknowledges that, if an Exchanging Investor is a
United States person for U.S. federal income tax purposes, either (i) the Company must be provided with a correct taxpayer identification number (“TIN,” generally a person’s social security or federal employer
identification number) and certain other information on a properly completed and executed Internal Revenue Service (“IRS”) Form W-9, or (ii) another basis for exemption from backup
withholding must be established. The Investor further acknowledges that, if an Exchanging Investor is not a United States person for U.S. federal income tax purposes, the Company must be provided with a properly completed and executed IRS Form W-8BEN, IRS Form W-8BEN-E, IRS Form W-8IMY (and all required attachments) or other applicable
IRS Form W-8, attesting to that non-U.S. Exchanging Investor’s foreign status and certain other information, including information establishing an exemption from
withholding under Sections 1471 through 1474 of the Internal Revenue Code of 1986, as amended (the “Code”). The Investor further acknowledges that any Exchanging Investor may be subject to 30% U.S. federal withholding or 24% U.S.
federal backup withholding on certain payments made to such Exchanging Investor unless such Exchanging Investor properly establishes an exemption from, or a reduced rate of, such withholding or backup withholding. See Exhibit C for certain
additional information. The Company and its agents shall be entitled to deduct and withhold from any consideration payable pursuant to this Agreement such amounts as are required to be deducted or withheld under applicable law. To the extent any
such amounts are withheld and remitted to the appropriate taxing authority, such amounts shall be treated for all purposes as having been paid to the Exchanging Investor to whom such amounts otherwise would have been paid. 

20.    Section and Other Headings. The section and other headings contained in Agreement are for reference purposes only and shall
not affect the meaning or interpretation of this Agreement. 
 [SIGNATURE PAGE FOLLOWS] 

  
 12 

 
			
	 Very truly yours,
  

APELLIS PHARMACEUTICALS, INC.

		
	By	 	  

		 	Name: Timothy Sullivan
		 	Title: Chief Financial Officer

  
 13 

 Please confirm that the foregoing correctly sets forth the agreement between the Company and the Investor by
signing in the space provided below for that purpose. 
  

			
	AGREED AND ACCEPTED:
	
	Investor:
	[_____________],
	in its capacity as described in the first paragraph hereof
		
	By	 	  

		 	Name:
		 	Title:

  
 14 

 EXHIBIT A 

Exchanging Investor Information 
  

			
	 Exchanging Investor
	  	 Aggregate Principal Amount of Exchanged
Notes

  
  

  
 A-1 

 EXHIBIT B.1 

Exchanging Investor: 
  

 
  

Investor Address: 
  

 
  

 
  

Telephone:                        
                                         
                        
 Country of
Residence: 
  
  

Taxpayer Identification Number: 
  

Account for Notes: 
 DTC Participant
Number:                                        
                                         
               
 DTC Participant
Name:                                        
                                         
                    
 DTC Participant Phone Number:
                                         
                                         
     
 DTC Participant Contact
Email:                                        
                                         
        
 FFC Account
#:                                        
                                         
                                 

Account # at
Bank/Broker:                                       
                                         
                
 Account for Shares (if different from Notes): 

DTC Participant
Number:                                        
                                         
                
 DTC Participant
Name:                                        
                                         
                    
 DTC Participant Phone Number:
                                         
                                         
    
 DTC Participant Contact
Email:                                        
                                         
        
 FFC Account
#:                                        
                                         
                                 

Account # at
Bank/Broker:                                       
                                         
                 
 Exchanging Investor Address: 

 
  

 
  

 

Telephone:                        
                                         
                                         
       
 Country of Residence: 

 
 Taxpayer Identification Number: 

 
  

  
 B.1-1 

 EXHIBIT B.2 

Exchange Procedures 

NOTICE TO INVESTOR 
 These are the
Exchange Procedures for the settlement of the exchange of 3.500% Convertible Senior Notes due 2026, CUSIP 03753UAB2 (the “Exchanged Notes”) of, a Delaware corporation (the “Company”), for the Shares to be issued as
Exchange Consideration (as defined in and pursuant to the Agreement between you and the Company), which is expected to occur on or about August 4, 2022. To ensure timely settlement for the Exchange Consideration, please follow the instructions
as set forth below. 
 These instructions supersede any prior instructions you received. Your failure to comply with these instructions may delay your
receipt of the Exchange Consideration. 
 If you have any questions, please contact Yun Xie of J. Wood Capital Advisors LLC at 917-727-9869. 
 To deliver Exchanged Notes: 

You must direct the eligible DTC participant through which you hold a beneficial interest in the Exchanged Notes on August 4, 2022,
no later than 9:00 a.m., New York City time, to perform a free delivery through DTC for the aggregate principal amount of Exchanged Notes set forth on Exhibit A of the Agreement to be exchanged for Shares. 

To receive Exchange Consideration: 
 You must direct the
eligible DTC participant on August 4, 2022, no later than 9:00 a.m., New York City time, to perform a free delivery through DTC for the aggregate principal amount of Exchanged Notes set forth on Exhibit A of
the Agreement to be exchanged for Shares. 
 American Stock Transfer & Trust Company is the Transfer Agent and Registrar for the Common Stock. 

Closing: On August 4, 2022, after the Company receives your Notes and your delivery instructions as set forth above, and subject to
the satisfaction of the conditions to Closing as set forth in your Exchange Agreement, the Company will deliver the Exchange Consideration in respect of the Exchanged Notes in accordance with the delivery instructions above. 

  
 B.2-1 

 EXHIBIT C 

Under U.S. federal income tax law, a holder who exchanges Notes for Shares generally must provide such holder’s correct TIN on a properly completed and
executed IRS Form W-9 (available from the Company or at www.irs.gov/pub/irs-pdf/fw9.pdf) or otherwise establish a basis for exemption from backup withholding. A TIN
is generally an individual holder’s social security number or a holder’s employer identification number. If the correct TIN is not provided, the holder may be subject to a $50 penalty imposed under Section 6723 of the Code. In
addition, certain payments made to holders may be subject to U.S. backup withholding (currently set at 24% of the payment). If a holder is required to provide a TIN but does not have a TIN, the holder should consult its tax advisor regarding how to
obtain a TIN. Certain holders (including corporations and non-U.S. holders) are not subject to these backup withholding and reporting requirements. 

A non-U.S. holder (i) will be subject to 30% U.S. federal withholding unless such holder establishes an exemption
from, or a reduced rate of, such withholding, and (ii) must establish its status as an exempt recipient from backup withholding and can do so by submitting a properly completed IRS Form W-8BEN, IRS
Form W-8BEN-E, IRS Form W-8IMY (and all required attachments), or other applicable IRS Form
W-8 (available from the Company or at www.irs.gov), signed, under penalties of perjury, attesting to such holder’s exempt foreign status. This form also may establish an exemption from withholding
under Section 1471 through 1474 of the Code. 
 U.S. backup withholding is not an additional tax. Rather, the U.S. federal income tax liability of
persons subject to backup withholding will be reduced by the amount of tax withheld. If withholding results in an overpayment of taxes, a refund may be obtained provided that the required information is timely furnished to the IRS. Holders are
urged to consult their tax advisors regarding how to complete the appropriate forms and to determine whether they are exempt from backup withholding or other withholding taxes. 

  
 C-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00347-of-00352.parquet"}]]